Astera Labs climbs as bullish $250 target keeps Trainium3-driven Scorpio-X thesis in focus
Astera Labs shares rose about 4.4% as investors continued to price in a recent bullish analyst move that lifted its price target to $250 from $225. The note tied upside to expected Scorpio-X switch revenue beginning in Q3 2026 tied to Trainium3 deployments.
1. What’s moving the stock
Astera Labs (ALAB) traded higher Thursday, April 23, 2026, extending a multi-day move that followed a high-profile price-target increase to $250 from $225 with an Outperform rating. The continued bid appears tied to traders leaning into the ramp narrative for Astera’s switching platform, with attention centered on incremental revenue opportunities tied to next-generation AI infrastructure buildouts. (insidermonkey.com)
2. The catalyst investors are keying on
The bullish thesis highlighted Scorpio-X as a driver of a step-up in switching revenue, with expectations that Trainium3-related deployments begin contributing in Q3 2026. The same view modeled Scorpio switch revenue rising sharply from about $130 million in 2025 to roughly $390 million in 2026, keeping near-term enthusiasm focused on visibility into hyperscaler deployments and product-cycle timing. (computing.net)
3. What to watch next
The next major scheduled catalyst is Astera Labs’ first-quarter 2026 results, set for after the close on May 5, 2026, with management slated to host a conference call the same day. With the stock already reacting to forward product-cycle optimism, the market’s near-term sensitivity is likely to be highest around guidance, customer-demand commentary, and any update on timing for Scorpio-X-related shipments and adoption. (insidermonkey.com)